Your browser doesn't support javascript.
loading
Antithrombotic Therapy in Patients Undergoing Percutaneous Left Atrial Appendage Occlusion.
Galea, Roberto; Räber, Lorenz.
Afiliación
  • Galea R; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: https://twitter.com/RaberLorenz.
  • Räber L; Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: lorenz.raeber@insel.ch.
Interv Cardiol Clin ; 13(4): 543-552, 2024 Oct.
Article en En | MEDLINE | ID: mdl-39245553
ABSTRACT
Percutaneous left atrial appendage closure (LAAC) is a valid alternative to oral anticoagulation to prevent ischemic stroke in patients with atrial fibrillation.The devices approved in Europe and United States for percutaneous LAAC contain metal and temporary antithrombotic therapy is strongly recommended following implantation to prevent thrombus formation on the atrial device surface. There is still uncertainty regarding to the optimal antithrombotic drug regimen after device implantation for several reasons. Thus, this review aims at summarizing the available evidence and the remaining challenges related to the management of antithrombotic therapy in the context of LAAC procedure.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrilación Atrial / Apéndice Atrial / Fibrinolíticos Límite: Humans Idioma: En Revista: Interv Cardiol Clin Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrilación Atrial / Apéndice Atrial / Fibrinolíticos Límite: Humans Idioma: En Revista: Interv Cardiol Clin Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos